Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Joan T. Garrett¹, Anindita Chakrabarty¹ and Carlos L. Arteaga^{1,2,3}

¹ Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

² Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

³ Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Correspondence to: Carlos L. Arteaga, email: carlos.arteaga@vanderbilt.edu

Keywords: cancer, combination therapy, mTOR, PI3K, receptor tyrosine kinases, oncotarget

Received: November 23, 2011,

Accepted: November 23, 2011,

Published: December 31, 2011

Copyright: © Garrett et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT:

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) axis regulates essential cellular functions including cell survival, proliferation, metabolism, migration, and angiogenesis. The PI3K pathway is activated in human cancers by mutation, amplification, and deletion of genes encoding components of this pathway. The critical role of PI3K in cancer has led to the development of drugs targeting the effector mechanisms of this signaling network. Recent studies have shown that inhibition at multiple levels of the PI3K pathway results in FOXO-dependent feedback reactivation of several receptor tyrosine kinases (RTKs) which, in turn, limit the sustained inhibition of this pathway and attenuates the action of therapeutic antagonists. This suggests that if used as single agents, PI3K pathway inhibitors may have limited clinical activity. We propose herein that to successfully target the output of the PI3K pathway in cancer cells, combination therapies that hinder these compensatory mechanisms should be used. Thus, combination therapies that target RTKs, PI3K, and mTOR activities may be required to maximize the clinical benefit derived from treatment with these inhibitors.

INTRODUCTION

The phosphatidylinositol 3-kinase (PI3K) pathway is an important regulator in cell survival, proliferation, and apoptosis. PI3K is a major signaling hub downstream of HER2 and other receptor tyrosine kinases (RTKs). PI3K activates AKT, SGK, PDK1, mTOR, and several other molecules involved in cell cycle progression and survival. The PI3K pathway is one of the most frequently altered networks in cancer [1], with mutation and/or amplification of the genes encoding RTKs such as HER2 (*ERBB2*) and FGFR1, the PI3K catalytic subunits p110 α (*PIK3CA*) and p110 β (*PIK3CB*), the PI3K regulatory subunit p85 α (*PIK3R1*), the PI3K activator mutant K-RAS, the PI3K effectors AKT1, AKT2, PDK1, and loss of the lipid phosphatases PTEN and INPP4B. PI3K is activated by growth factor RTKs and G-protein-coupled receptors (GPCRs). PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP₂) to produce the second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP₃) [2, 3].

Upon formation of PIP₃, the pleckstrin homology (PH) domain of AKT and PDK1 colocalize at the plasma membrane, resulting in phosphorylation at T308 and activation of AKT. Negative regulation of this pathway is conferred by PTEN and INPP4B, which cleave a phosphate group in PIP₃ and PIP₂, respectively. AKT activates the mTOR-containing complex 1 (TORC1) which, via S6K and 4E-BP1, regulates mRNA translation and protein synthesis. mTOR is part of another complex (TORC2), which phosphorylates AKT at S473 and fully induces its catalytic activity. Little is known about the upstream activators of TORC2 although it is generally thought that growth factors, directly or indirectly, control its activity.

Class IA PI3K isoforms (PIK3C α , PIK3C β , and PIK3C δ) are heterodimeric proteins that contain a p110 catalytic subunit and a p85 regulatory subunit. Three genes, *PIK3CA*, *PIK3CB*, and *PIK3CD*, encode the homologous p110 α , p110 β , and p110 δ isozymes, respectively. p110 α and p110 β are ubiquitously expressed whereas p110 δ is

largely limited to immune and hematopoietic cells. The p110 α isozyme is necessary for growth of tumors driven by RTKs, mutant Ras, and/or *PIK3CA* mutations [4]. Conversely, p110 β lies downstream of GPCR signaling and ablation of p110 β , but not that of p110 α , impedes tumorigenesis in PTEN-deficient cells [5]. *PIK3CA* mutations are the most common genetic alterations of this pathway in breast cancer, where $\geq 80\%$ occur within “hot spots” of exons 9 and 20, corresponding to the helical (E542K and E545K) and kinase (H1047R) domains of p110 α . These mutations result in an enzyme with increased catalytic activity through unique mechanisms [6], but both induce similar features of transformation including growth factor- and anchorage-independent growth, and protection from anoikis [7].

The PI3K pathway and its upstream and downstream effectors include many potential targets for drug development in cancer. Drugs inhibiting this pathway at different levels used alone or in combination with chemotherapy, radiation, or other targeted therapies are being evaluated in preclinical and clinical trials and have been summarized recently [8, 9]

INHIBITION OF THE PI3K PATHWAY RESULTS IN FEEDBACK REACTIVATION OF MULTIPLE RTKS

Negative feedback regulation at different levels in the PI3K pathway has been well-documented [10-12]. These feedback loops may have evolved in multicellular organisms to manage growth and nutrient use by individual cells with that of the whole organism [13]. One of the first indications of negative-feedback regulation of the pathway in cancer was found with rapamycin. The macrolide rapamycin and its analogs (rapalogs) complex with FK506-binding protein (FKBP12); this complex then binds to mTOR and, as a result, inhibits the kinase activity of TORC1 but not TORC2. Inhibition of TORC1 and downstream S6K with the rapalog everolimus derepresses levels of insulin receptor substrate (IRS)-1 expression leading to activation of PI3K and phosphorylation of AKT at S473 in both cancer cell lines and tumors of patients [14-16]. These findings may explain the limited clinical activity of TORC1 inhibitors when used as single agents. This observation led to a phase I study of a TORC1 inhibitor and an IGF-IR neutralizing antibody. The combination of both drugs showed interesting clinical activity in patients with luminal B metastatic breast cancer [17]. Inhibition of mTORC1 was also shown to activate the MAPK pathway [18]. In a study of patients treated with the TORC1 inhibitor everolimus, tumors exhibited strong upregulation of ERK phosphorylation. This feedback loop was shown to depend on an S6K-PI3K-Ras pathway.

One approach to circumvent the feedback caused by rapalogs is use of compounds that target the ATP-binding cleft of mTOR and are thus active against both TORC1 and

TORC2. Rodrik-Outmezguine *et al.* recently reported that inhibition of TORC1/2 with the small molecule AZD8055 resulted in dephosphorylation of AKT at S473 and a rapid but only transient inhibition of T308 P-AKT. Inhibition of TORC1/2 also relieved feedback inhibition of RTKs resulting in formation of PIP₃ and rephosphorylation of AKT at T308. Upon recovery of T308 P-AKT, multiple AKT substrates, including FoxO, regained phosphorylation, suggesting T308 P-AKT is catalytically competent. This reinduction of T308 P-AKT and AKT substrates was sensitive to inhibition of AKT but not readdition of mTOR kinase inhibitors, thus demonstrating that such reinduction results from hyperactivity of PI3K. Finally, combined inhibition of mTOR kinase (TORC1/2) and RTKs prevented the rebound of T308 P-AKT and resulted in enhanced cell death and tumor regressions *in vivo* [19].

Similar to the report using TORC1/2 inhibitors, Chandarlapaty and colleagues showed that blockade of AKT (upstream of TORC1 and downstream of TORC2) with an allosteric kinase inhibitor also resulted in enhanced transcription and phosphorylation of multiple RTKs including HER3, IGF-1R, and insulin receptor [20]. These changes are the result of both inhibition of TORC1 and also derepression of FOXO-dependent transcription. Like for rapalogs, inhibition at the level of p110 also results in a compensatory activation of ERK signaling [21]. The activation of HER (ErbB) receptors, as indicated by increased expression of HER3 and binding of adaptor molecules to phosphorylated HER2-HER3 dimers, collectively result in enhanced ERK signaling. The combination of PI3K inhibitors with either HER2 or MEK inhibitors resulted in decreased proliferation, enhanced cell death and superior anti-tumor activity *in vivo* compared with single agent PI3K inhibitors.

INHIBITION OF PI3K IS INCOMPLETE WITH SINGLE AGENTS

Cancer cells that depend on the HER2 oncogene rely heavily of PI3K activity [22, 23]. In these cells, PI3K is activated by phosphorylated HER2-HER3 dimers. Knockdown of HER3, the adaptor that directly binds PI3K (p85) in these cells, inhibits PI3K and viability of HER2-dependent breast cancer cells [24]. In a clinical trial where patients with HER2+ breast cancer were treated with the HER2 TKI lapatinib, there was significant upregulation of HER3 protein without inhibition of S473-AKT in tumor core biopsies obtained at 2 weeks of treatment [25, 26]. This result was somewhat surprising as tumors were shrinking during therapy with the single agent TKI. The rebound of HER3 protein levels was secondary to the initial inhibition of PI3K-AKT and derepression of FoxO-mediated HER3 mRNA transcription. Recovery of HER3 phosphorylation was secondary to residual HER2 kinase activity and maintenance of ligand-independent HER2-

HER3 dimers. Inhibition of HER3 with either siRNA or a neutralizing receptor antibody sensitized to lapatinib, providing evidence that the upregulation of HER3 mRNA and rebound phosphorylation of the HER3 RTK were counteracting the full effect of lapatinib [25].

The data summarized above suggest that single agent HER2 inhibitors cannot block completely the signaling output from HER2 to HER3-PI3K-AKT. They also suggest that surrogate markers of PI3K activity would be valuable metrics to assess the magnitude of therapeutic pharmacodynamic inhibition in tumors that depend on oncogenes that activate and depend on PI3K. Genes encoding most glycolytic enzymes are under dominant transcriptional control by PI3K/AKT [27]. Further, activation of AKT stimulates glucose import and metabolism [28]. Thus, a rapid decrease in [^{18}F]-fluoro-deoxyglucose positron emission tomography (FDG-PET) uptake may represent a surrogate marker of inactivation of the PI3K/AKT pathway. In a recent study, we treated HER2+ BT474 xenografts with the combination of lapatinib and U3-1287, a neutralizing HER3 monoclonal antibody [29, 30]. To determine whether the combined inhibition of HER2 and HER3 with lapatinib and U3-1287 improved the inhibition of PI3K over each single agent, we used FDG-PET imaging. Baseline tumor [^{18}F] FDG uptake was measured; mice were then randomized to control vehicle, lapatinib, U3-1287, or both drugs

combined and re-imaged on day 14. Treatment with the combination resulted in a statistically significant decrease in [^{18}F]FDG tumor uptake compared to both vehicle- and lapatinib-treated mice (Figure 1A and B). Treatment with U3-1287 alone had no effect on [^{18}F]FDG uptake (data not shown). At 14 days of therapy there was no statistically difference in tumor volume for any of the treatment groups [25], suggesting that [^{18}F]FDG uptake can be used as an early imaging biomarker predictive of response to a PI3K inhibitory therapy. Immunoblot analysis of tumor lysates from tumors harvested at 28 days of treatment revealed greater inhibition of P-AKT and P-Erk in xenografts treated with the combination compared to xenografts treated with lapatinib alone (Figure 1C). After 4 weeks of therapy, tumors treated with the combination exhibited a markedly reduced volume compared to the lapatinib and control arms [25]. These results suggest that a single-agent inhibitor is ineffective at completely blocking the PI3K pathway and that combination approaches are needed to block feedback-regulated pathways thus completing blockade of the PI3K axis.

In a second example, we reported that treatment with the pan-PI3K inhibitor XL-147 (Exelixis) was followed by up-regulation of expression and phosphorylation of several RTKs, including HER3, InsR, IGF-1R, FGFR2/3 [31]. Knockdown of FoxO1 and FoxO3a transcription factors suppressed the induction of HER3, InsR, IGF-1R,

Figure 1: Inhibition of HER3 sensitizes cells to the HER2 inhibitor lapatinib *in vivo*. Female athymic mice were injected with BT474 cells as described [25]. Once tumors reached a volume $\geq 250 \text{ mm}^3$, mice were randomized to 1) 20 mg/kg normal human IgG i.p. twice a week and vehicle daily via orogastric gavage (control), 2) lapatinib (100 mg/kg daily via orogastric gavage), 3) U3-1287 (20 mg/kg i.p. twice a week), or 4) a combination of lapatinib and U3-1287. Treatment was administered for 4 weeks. (A,B). Tumor-bearing mice were imaged at baseline for [^{18}F]FDG uptake, treated as described above and re-imaged on day 14 ($n=8-11$ per group). (A). Images from a representative mouse show [^{18}F]FDG uptake pre- and post-treatment. (B). top: Plot of the % change in [^{18}F]FDG uptake at day 14 compared to baseline is shown. (B). bottom: Raw values of [^{18}F]FDG %ID/g at 14 days post-treatment. Boxes indicate 25th to 75th percentile of values. The solid line indicates the median value and external lines show the complete range. (C). At the end of 4 weeks of treatment, mice were sacrificed either 1 or 24 h after the last dose of lapatinib. Tumor cell lysates were prepared and separated in a 7% SDS gel followed by immunoblot analysis with the indicated antibodies.

and FGFR2 mRNAs upon inhibition of PI3K. In HER2+ cells, HER3 was the main RTK that became reactivated upon treatment with XL-147. Further, addition of lapatinib or the HER2 antibody trastuzumab to XL-147 in mice with established BT474 xenografts resulted in better growth inhibition as well as reduction of tumor levels of P-HER3, P-AKT, and P-S6.

The biologically relevant RTKs that compensate for inhibition of PI3K-AKT in cancers expressing low levels of HER2 are less clear. We have examined this question in ER+/HER2-negative MCF7 human breast cancer cells which also harbor an activating E545K mutation in *PIK3CA* (p110 α) [32]. In these cells, treatment with the pan-PI3K inhibitor BKM120 [33] over a time-course was followed by upregulation of total and phosphorylated InsR at 24 h (Figure 2A,B). The compensatory upregulation of total and P-InsR upon inhibition of PI3K suggested that combined inhibition of InsR and PI3K would synergistically inhibit tumor cell viability. Therefore, we transfected MCF7 cells with InsR siRNA oligonucleotides in combination with BKM120. The combination of InsR

knockdown and BKM120 resulted in a statistical reduction in cell growth compared to either treatment alone. This was further confirmed by immunoblot of PARP, a biomarker of cell death (Figure 2C). These data further suggest that upon inhibition of PI3K, PI3K-dependent cells upregulate RTKs that hamper the efficacy of a single-agent PI3K pathway inhibitor. Taken together, the findings presented here and elsewhere [14, 18-21, 25, 31] reveal a complex network of feedback regulation between PI3K, mTOR, and RTKs.

CLINICAL IMPLICATIONS

These findings have obvious translational implications for the treatment of PI3K-pathway dependent cancers. The relief of negative feedback loops upon inhibition of different levels in the PI3K-AKT pathway and subsequent reactivation of RTKs suggest that, if used as single agents, PI3K inhibitors will have suboptimal clinical activity. It is possible that relief of these feedback

Figure 2: PI3K inhibition in MCF7 cells results in compensatory upregulation of InsR. (A). MCF7 cells were treated with 1 μ M BKM120 for the indicated time points; at these times cells were harvested and cell lysates prepared. Cell lysates (500 μ g) were hybridized with phospho-RTK arrays (R&D Systems) according to the manufacturer's instructions. (B). Fifty μ g/lane of cell lysate from A were separated by SDS-PAGE followed by transfer to nitrocellulose and immunoblot analysis with the indicated antibodies. (C). MCF7 cells were transfected with 50 nM of control or InsR siRNA and seeded in 6-well plates followed by treatment with 1 μ M BKM120. Seven days after transfection, the cells were harvested and counted in a Coulter counter (top panel). Three days post-transfection (or 24 h after treatment with BKM120) cell lysates were prepared and subjected to immunoblot analyses for InsR, PARP, and Actin (control; bottom panel). Each bar represents mean $\pm$ SE cell number in triplicate wells (* p <0.05).

loops is also occurring in non-tumor host tissues and thus ameliorating drug-related toxicities. Combined targeting of different levels of the PI3K pathway, i.e., TORC1/2 and p110, RTK and p110; RTK and TORC1/2, etc., in order to more completely suppress its signaling output, have not been fully explored. Whether those combined approaches limit feedback reactivation and, as a result, block the pathway more strongly and/or whether they are clinically well tolerated and feasible remains to be determined. Compensatory feedback may not be limited to RTKs. For example, inhibition of PI3K in prostate cancer cells activates signaling by the androgen receptor (AR) and inhibition of the AR, in turn, activates AKT signaling by reducing levels of the AKT phosphatase PHLPP [34]. Whether similar coordinate regulation of steroid receptors exists in other hormone-dependent tumors remains to be established. Interestingly, however, experimental and clinical evidence suggests that hyperactivation of the PI3K pathway promotes antiestrogen resistance in breast cancer [35], suggesting that simultaneous targeting of PI3K and ER pathways may be effective in ER+ breast cancer [36]. The ability of these combinations to perform in the clinic is currently the focus of active investigation. Ideally, these studies should confirm whether the feedback reactivation seen in the laboratory in cancer cells following PI3K-AKT inhibition is of the same nature in primary tumors.

REFERENCES

- Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. *Cancer Cell*. 2007; 12:104-107.
- Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. *Annu Rev Biochem*. 1998; 67:481-507.
- Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. *Science*. 1991; 254:274-277.
- Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? *Curr Opin Cell Biol*. 2009; 21:199-208.
- Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. *Nature*. 2008; 454:776-779.
- Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. *Proc Natl Acad Sci U S A*. 2008; 105:2652-2657.
- Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearlman RV, Cantley LC, Brugge JS. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. *Cancer Res*. 2005; 65:10992-11000.
- Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. *Biochim Biophys Acta*. 2008; 1784:159-185.
- Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer*. 2009; 9:550-562.
- Radimerski T, Montagne J, Hemmings-Mieszczak M, Thomas G. Lethality of *Drosophila* lacking TSC tumor suppressor function rescued by reducing dS6K signaling. *Genes Dev*. 2002; 16:2627-2632.
- Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. *J Cell Biol*. 2004; 167:399-403.
- Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. *Trends Biochem Sci*. 2005; 30:35-42.
- Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat Rev Genet*. 2006; 7:606-619.
- O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res*. 2006; 66:1500-1508.
- Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. *Cancer Res*. 2005; 65:7052-7058.
- Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/ phosphatidylinositol 3-kinase cascade. *Mol Cancer Ther*. 2005; 4:1533-1540.
- Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, Roda D, Prudkin L, Stein MN, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors. *ASCO Meeting Abstracts*. 28:3008.
- Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. *J Clin Invest*. 2008; 118:3065-3074.
- Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N. mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling. *Cancer Discovery*. 1:248-259.
- Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. *Cancer*

Cell. 19:58-71.

21. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N *et al.* PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. *Oncogene*. 30:2547-2557.
22. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira S-M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. *Proceedings of the National Academy of Sciences*. 2009; 106:22299-22304.
23. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. *Clin Cancer Res*. 16:3670-3683.
24. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. *Cancer Res*. 2008; 68:5878-5887.
25. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinley E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. *Proc Natl Acad Sci U S A*. 108:5021-5026.
26. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. Loss of phosphatase and tensin homolog or phosphoinositide-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. *J Clin Oncol*. 29:166-173.
27. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. *Nat Med*. 2004; 10:594-601.
28. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. *Oncogene*. 2005; 24:7435-7442.
29. Freeman D, Ogbagabriel S, Rothe M, Radinsky R, Treder M. Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors. *AACR Meeting Abstracts*. 2008; 2008:LB-21-.
30. Treder M, Hartmann S, Ogbagabriel S, Borges E, Green L, Kang J, Radinsky R, Rothe M, Freeman D. Fully human Anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo. *AACR Meeting Abstracts*. 2008; 2008:LB-20-.
31. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. *Proc Natl Acad Sci U S A*.
32. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A *et al.* Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. *Breast Cancer Res Treat*. 121:53-64.
33. Burger MT, Pecchi S, Wagman A, Ni Z-J, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S, Frazier K, Ng S, Smith A, Verhagen J, Haznedar J, Huh K *et al.* Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. *ACS Medicinal Chemistry Letters*. 2:774-779.
34. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. *Cancer Cell*. 19:575-586.
35. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer. *J Clin Oncol*.
36. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, Gonzalez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG *et al.* ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. *Cancer Discov*. 1:338-351.

This page intentionally left blank

This page intentionally left blank